Skip to main content
. 2015 Oct;4(5):503–514. doi: 10.3978/j.issn.2218-6751.2015.06.02

Figure 1.

Figure 1

Example of a biomarker-driven treatment pathway for NSCLC, whereby mutations in EGFR or ALK drive targeted therapy selection, while patients with tumors negative for these biomarkers have therapy guided by histology and other clinical factors. NSCLC, non-small cell lung cancer; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase.